about
Short peptides derived from the BAG-1 C-terminus inhibit the interaction between BAG-1 and HSC70 and decrease breast cancer cell growthThe outcome of B-cell receptor signaling in chronic lymphocytic leukemia: proliferation or anergyProtein recognition by short peptide reversible inhibitors of the chromatin-modifying LSD1/CoREST lysine demethylaseEpigenetic modulators as therapeutic targets in prostate cancerThe first biologically active synthetic analogues of FK228, the depsipeptide histone deacetylase inhibitorBAG-i expression in human breast cancer: interrelationship between BAG-1 RNA, protein, HSC70 expression and clinico-pathological data.E-ring modified steroids as novel potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1.Thioflavin S (NSC71948) interferes with Bcl-2-associated athanogene (BAG-1)-mediated protein-protein interactions.PI3Kδ inhibition elicits anti-leukemic effects through Bim-dependent apoptosisSurface IgM stimulation induces MEK1/2-dependent MYC expression in chronic lymphocytic leukemia cells.Glycosylation of surface Ig creates a functional bridge between human follicular lymphoma and microenvironmental lectins.Stimulation of surface IgM of chronic lymphocytic leukemia cells induces an unfolded protein response dependent on BTK and SYK.The histone deacetylase inhibitors vorinostat and romidepsin downmodulate IL-10 expression in cutaneous T-cell lymphoma cells.A cyclic peptide inhibitor of HIF-1 heterodimerization that inhibits hypoxia signaling in cancer cells.Molecular profiling of the invasive tumor microenvironment in a 3-dimensional model of colorectal cancer cells and ex vivo fibroblastsStratifying risk of recurrence in stage II colorectal cancer using deregulated stromal and epithelial microRNAs.Annexin A3 is a mammary marker and a potential neoplastic breast cell therapeutic target.BAG-1 in carcinogenesis.Mcl-1.A combination of trastuzumab and BAG-1 inhibition synergistically targets HER2 positive breast cancer cellsBodyguards and assassins: Bcl-2 family proteins and apoptosis control in chronic lymphocytic leukaemia.The clinical and biological significance of MIR-224 expression in colorectal cancer metastasis.T-cell number and subtype influence the disease course of primary chronic lymphocytic leukaemia xenografts in alymphoid mice.BCR-signaling-induced cell death demonstrates dependency on multiple BH3-only proteins in a murine model of B-cell lymphoma.Differential induction of apoptosis in human breast cancer cell lines by phenethyl isothiocyanate, a glutathione depleting agent.FOXO3 expression during colorectal cancer progression: biomarker potential reflects a tumour suppressor role.MicroRNAs: key players in carcinogenesis and novel therapeutic targets.Will histone deacetylase inhibitors require combination with other agents to fulfil their therapeutic potential?Genomic disruption of the histone methyltransferase SETD2 in chronic lymphocytic leukaemia.A ribosome-related signature in peripheral blood CLL B cells is linked to reduced survival following treatment.PEITC-mediated inhibition of mRNA translation is associated with both inhibition of mTORC1 and increased eIF2α phosphorylation in established cell lines and primary human leukemia cells.Investigational epigenetically targeted drugs in early phase trials for the treatment of haematological malignancies.The meaning and relevance of B-cell receptor structure and function in chronic lymphocytic leukemia.BAG-1 is up-regulated in colorectal tumour progression and promotes colorectal tumour cell survival through increased NF-kappaB activity.Distinct promoters mediate constitutive and inducible Bcl-XL expression in malignant lymphocytes.BAG-1 proteins protect cardiac myocytes from simulated ischemia/reperfusion-induced apoptosis via an alternate mechanism of cell survival independent of the proteasome.The Nrf2 transcription factor contributes to resistance to cisplatin in bladder cancer.The histone deacetylase inhibitor, romidepsin, as a potential treatment for pulmonary fibrosis.Engagement of the B-cell receptor of chronic lymphocytic leukemia cells drives global and MYC-specific mRNA translation.A role for eukaryotic initiation factor 4B overexpression in the pathogenesis of diffuse large B-cell lymphoma.
P50
Q24321127-2EA61558-AD41-43A3-8647-3CA2D2347E56Q26865760-32F3304E-A30A-48A7-8685-79A8FA57BDC7Q27684725-EEBAA4B5-D766-4D4C-AE99-A546ED8636C2Q28071912-8F43C4B5-C13F-492E-8605-E26252968331Q28254544-59093B87-1546-4AA8-9D95-C3EBB3AF5F55Q30699989-9BE7799C-4B0F-4741-9E8C-D8F33A532172Q33222654-8BC9786D-3C8B-48B3-AB20-3B0D7E6E601EQ33494790-86E2532C-EA5A-4D37-BD1C-B6C1AFB1DDA0Q33785941-C8975510-1722-4C10-8B01-1835227F5926Q34029409-DC4B143A-90F0-4606-8BAE-566FF7D70B70Q34276522-F461EA82-5AE2-4B49-AE40-CD44DBF306D8Q34508337-AF03FE72-9220-431B-8A53-48E80C7554D8Q34672100-8EE12F29-7B6C-4632-86A8-D7A9F92D343BQ34782024-973A52C1-5E02-4AAB-958B-345749D97C9CQ35170178-94599020-A3F6-4AEA-9019-04F029D3A0BFQ35580945-AB6879FA-29A0-477F-8B6C-C341D2C8BEC2Q35669421-6679D5D6-B2DC-4968-AAE2-F00D99C65FE8Q35699747-A9D3E5AD-D2E1-495C-A17F-B783C4EB0225Q35913618-F74533E5-BAFD-4255-81E1-AE5017D38FCFQ35950783-F2BDE784-2C3B-4DE0-B685-11CDC8052645Q36085962-1B019338-4B93-4CA7-8AB7-3A703129E698Q36090214-5A28363D-AB18-4434-B849-E19810462707Q36245171-2BD84EB0-9431-44F1-A290-3FABA7D9F8C9Q36472505-A88808EE-B219-4311-B4DF-231848EDB2BDQ36502589-C7B3FA82-CE25-4695-A574-4E8FC069B8BAQ37040688-DE03D153-D941-49EC-9F24-B497D5208DBFQ37223100-9210D310-C045-4609-828A-823842B5EEB2Q37252722-134C180D-4E08-432C-817E-72927A2D9EFBQ37255665-F67AE3ED-94D9-492A-B2C9-2A7FE74EEB09Q37482750-C5731CE3-B6D0-4EA1-AFDB-4C1CD5CAF2FDQ37688853-A45F7E01-E0BA-410C-A7F4-1A7B1F177CBEQ38214120-3A9F89B2-5EFE-4FEF-B55E-E53DD429AEDFQ38232479-E3596A6A-78CB-4E6D-88AF-1C9A9EB80BA5Q38294434-82224DCC-5A2E-4CAB-8DCB-8F0E2498CB73Q38309488-290D77D8-6450-4F46-B47F-B2551F2C6802Q38344518-255BC4B9-8BBF-4372-A5A6-B37E32747543Q38391671-2E08584E-5E4F-4CC3-8F59-12AE8D987086Q38688113-8C6BCF62-2961-406E-AA91-3C2A8BAC5A97Q38825994-5058DE2B-75D5-4874-BF5F-B8E4C085AEE7Q39077324-470A5A52-7F95-440D-9F81-329FA1175F6A
P50
description
researcher ORCID ID = 0000-0002-9232-5691
@en
wetenschapper
@nl
name
G Packham
@ast
G Packham
@nl
Graham Packham
@en
Graham Packham
@es
type
label
G Packham
@ast
G Packham
@nl
Graham Packham
@en
Graham Packham
@es
altLabel
G Packham
@en
prefLabel
G Packham
@ast
G Packham
@nl
Graham Packham
@en
Graham Packham
@es
P1153
7004870900
P21
P31
P496
0000-0002-9232-5691